Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) Profit After Tax (2024 - 2025)

Xilio Therapeutics' Profit After Tax history spans 2 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, Profit After Tax rose 86.24% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$42.7 million, changed N/A, while the annual FY2024 figure was -$58.2 million, 23.77% up from the prior year.
  • Profit After Tax for Q3 2025 was -$1.9 million at Xilio Therapeutics, up from -$14.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$1.9 million in Q3 2025 and bottomed at -$17.2 million in Q1 2024.